Neuroendocrine Tumors

17 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms, Neoplasms, Germ Cell and Embryonal

Narrower: Carcinoid Tumor 2, Carcinoma, Medullary 1, Carcinoma, Neuroendocrine 3, Pheochromocytoma 2

Treatments and conditions

Neuroendocrine Tumors
Treatment and conditionWhere it standsTrials
61Cu-NODAGA-LM3 + Comparator for neuroendocrine tumorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
68-Gallium DOTATATE for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lurbinectedin for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LUTETIUM OXODOTREOTIDE LU-177 for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pheochromocytomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pheochromocytomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab + lenvatinib for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sbrt for neuroendocrine tumorsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Temozolomide for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumorsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.